Overview

Update
Primary Role
General Partner @
Investments
28 Investments in 12 Companies
Gender:
Female
Location:
San Francisco
Social:

Person Details

Update

Dr. Beth Seidenberg is a partner at Kleiner Perkins Caufield & Byers focused on life science investing. She works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health.

Since joining KPCB in 2005, Beth has incubated five companies and serves on the board of directors of 3-V Biosciences, Armo Biosciences, Atara, Auxogyn, Breathe Technologies, Epizyme, iPierian, Redbrick Health and TESARO.

Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc.

Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals.

Beth received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.

Jobs (4)

Update
Current

General Partner

2005 - Current   (over 11 years)
Past
Started
Ended
Title
Company
Unknown
Unknown
Senior Executive, Research and Development
Unknown
Unknown
Vice President, Global Development, and Chief Medical Officer
Unknown
Unknown
Senior Executive - R&D
DateInvested InRoundDetails
Jun, 2016$67.8M / Series B
Feb, 2016$50M / Series C
Mar, 2015$15.2M / Venture (Lead)
Jan, 2015$810k / Venture
Dec, 2014$28.5M / Series D (Lead)
Dec, 2014$38M / Series B (Lead)
Jun, 2014$7.3M / Series D (Lead)
May, 2014$30M / Series B
May, 2014$5.25M / Series A (Lead)
Jan, 2014$13.5M / Series B
Dec, 2013$38.5M / Series B
Nov, 2013$20M / Series A (Lead)
Oct, 2013$13M / Series A (Lead)
Sep, 2013$70M / Series D (Lead)
Sep, 2013$30M / Private Equity (Lead)
Jun, 2013$20M / Series C
Apr, 2013$14M / Private Equity
Oct, 2012$8.09M / Venture
Jan, 2012$20M / Venture (Lead)
Aug, 2011$5M / Series D
Jun, 2011$101M / Series B (Lead)
Nov, 2010$28.97M / Series B
May, 2010$23M / Series C
Oct, 2009$32M / Series B
Jul, 2009$30M / Series B
Jul, 2009$11.5M / Venture
Apr, 2009$15M / Series C (Lead)
Mar, 2008$15M / Series B (Lead)

Add Memberships

Add Images

Add Videos